C.R. Bard concluded its defense in a product liability and negligence trial involving plaintiff Robert Cook's infected port catheter. The global medical technology company argues it bears no responsibility for Cook's infection, asserting the contamination occurred in the home environment rather than during implantation or manufacture.
The case centers on whether Bard's catheter design or manufacturing process created an unreasonable risk of infection, or whether post-implantation handling caused the harm. Bard's defense strategy emphasizes the break in causation between its product and Cook's injury, contending that home care practices—not the device itself—introduced the infection.
This litigation reflects broader tensions in product liability law regarding medical devices. Manufacturers typically face two theories of liability: design defect and failure to warn. Bard's argument attempts to shift responsibility to the user or healthcare provider, a common defense tactic in catheter infection cases. The company must demonstrate that its product met applicable standards and that subsequent human conduct severed any causal link to injury.
Cook's counsel likely argued that the device's design, materials, or manufacturing specifications created conditions facilitating infection, or that Bard failed to provide adequate warnings about infection risks. Medical device manufacturers face heightened scrutiny under products liability doctrine, particularly when infections can be traced to device contact.
The trial outcome carries implications for device manufacturers nationwide. Courts increasingly examine whether manufacturers could have implemented safer designs or clearer labeling regarding infection prevention. A verdict for Cook could expand liability exposure for catheter producers. A defense verdict would reinforce the principle that post-implantation patient conduct breaks the causal chain between device and injury.
Bard faces significant litigation over catheter products, particularly vaginal mesh and other implanted devices. This trial tests whether juries will accept the company's argument that home-based infection sources shield manufacturers from liability despite known infection risks.
THE TAKE